Ricerc@Sapienza

Malaria mortality rates have fallen by 47% globally since 2000 and by 54% in the African region, but they are still a major problem. Malaria is caused by Plasmodium parasites, vectored to people through Anopheles mosquitoes, which mainly bite between dusk and dawn. Currently, a growing number of Plasmodium species and strains developed resistance to the most commonly used anti-malarial drugs. Chloroquine (CQ), the most commonly used anti-malarial drug, actually is not effective in a number of cases, and growing Plasmodium resistance has been already observed to artemisinin.

Several intralesional therapeutic protocols have been proposed for the treatment of Peyronie's disease. Among all, hyaluronic acid (HA) and verapamil have been differently tested. We aimed to evaluate the efficacy of intralesional verapamil (ILVI) compared with intralesional HA in patients with early onset of Peyronie's disease (PD). This is a multi-centre prospective double-arm, randomized, double-blinded study comparing ILVI vs. intralesional HA after 12-weeks. Sexually active men, older than 18 years and affected by the acute phase of PD were eligible for this study.

Multidrug resistance (MDR) in cancer cells is often associated with overexpression of ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp/ABCB1), multidrug resistance-associated protein 1 (MRP1/ABCC1) and breast cancer resistance protein (BCRP/ABCG2). Modulators of these transporters might be helpful in overcoming MDR. Moreover, exploiting collateral sensitivity (CS) could be another approach for efficient treatment of cancer.